论文部分内容阅读
随着抑郁症越来越被重视,抗抑郁的新药不断涌现。阿戈美拉汀(agometatine)作为第一个褪黑激素类抗抑郁药,由法国某公司研发,属于萘环类化合物,能同时激动MT1和MT2受体,且兼有拮抗5HT2C受体作用,可调节睡眠觉醒周期,调节患者的睡眠结构增加睡眠[1]。本研究主要对阿戈美拉汀原料药进行长期毒性研究,观察该药物对实验动物所产生的毒性反应、毒性靶器官及恢复情况,为临床安全用药提供参考。
With the increasing emphasis on depression, new antidepressants are emerging. As the first melatonin-based antidepressant, agometatine, developed by a French company, belongs to the class of naphthalene ring compounds and can simultaneously agonize MT1 and MT2 receptors and antagonize 5HT2C receptor. Adjustable sleep awakening cycle, regulating the patient's sleep architecture to increase sleep [1]. In this study, the long-term toxicity of agomelatine APIs was studied. The toxicity, target organs and recovery of the drug were observed. The results provided references for the clinical use of drugs.